BS_8Z3SCKB5
subependymal giant cell astrocytoma(SEGA)
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- subependymal giant cell astrocytoma(SEGA)
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- subependymal giant cell astrocytoma(SEGA)
- overall_survival_months
- 47.273324572930356
- age_years
- 10.679
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.661
- INTERFERON_ALPHA_RESPONSE+0.618
- INTERFERON_GAMMA_RESPONSE+0.549
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.535
- IL6_JAK_STAT3_SIGNALING+0.499
- FATTY_ACID_METABOLISM+0.470
- ADIPOGENESIS+0.458
- ALLOGRAFT_REJECTION+0.445
- COAGULATION+0.437
- PROTEIN_SECRETION+0.414
Top 10 suppressed
- E2F_TARGETS-0.438
- G2M_CHECKPOINT-0.382
- MYC_TARGETS_V2-0.303
- WNT_BETA_CATENIN_SIGNALING-0.233
- MITOTIC_SPINDLE-0.232
- SPERMATOGENESIS-0.160
- MYC_TARGETS_V1-0.136
- NOTCH_SIGNALING-0.129
- TGF_BETA_SIGNALING-0.110
- UV_RESPONSE_DN-0.095
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3TQSE8HF | subependymal giant cell astrocytoma(SEGA) | — | 0.954 |
| 2 | BS_R634WKN7 | subependymal giant cell astrocytoma(SEGA) | — | 0.930 |
| 3 | BS_VARR255N | pilocytic astrocytoma | — | 0.905 |
| 4 | SRR1078879 | GTEX | — | 0.895 |
| 5 | SRR15030885 | — | — | 0.891 |
| 6 | BS_BKQZ550R | pilocytic astrocytoma | — | 0.891 |
| 7 | BS_X16PENSA | pilocytic astrocytoma | — | 0.891 |
| 8 | BS_HV8PFRBR | pilocytic astrocytoma | — | 0.888 |
| 9 | BS_JG9JZTA9 | low-grade glioma | — | 0.884 |
| 10 | BS_EYYMKWB7 | subependymal giant cell astrocytoma(SEGA) | — | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.661 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.618 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.549 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.535 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.499 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.470 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.458 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.445 | Idelalisib | — uncovered |
| COAGULATION | 0.437 | Binimetinib | — uncovered |
| PROTEIN_SECRETION | 0.414 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.382 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.359 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.347 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.342 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.341 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.326 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.311 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.281 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.274 | Idelalisib | — uncovered |
| PEROXISOME | 0.273 | Idelalisib | — uncovered |